News
Welcome to another installment of our CEF Market Weekly Review, where we discuss closed-end fund (“CEF”) market activity from both the bottom-up – highlighting...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
Infrastructure Capital Advisors (“Infrastructure Capital”) is a leading provider of investment management solutions designed to meet the needs of income-focused investors. Jay Hatfield is...
News
This article was written by Follow I am a dynamic finance professional with a Master’s in Banking & Finance from Université Paris 1 Panthéon-Sorbonne....
News
This article was written by Follow Daniel is an avid and active professional investor. He runs Crude Value Insights, a value-oriented newsletter aimed at...
News
Five companies priced IPOs this week, led by Birkenstock’s (BIRK) $1.5 billion offering. Three small issuers submitted initial filings. Birkenstock priced its IPO just...
News
GREETINGS FELLOW SHAREHOLDER The calendar third quarter of 2023 was overall a messy one for financial markets at large, and not particularly fun for...
News
ByYan Carrière-Swallow, Deputy Division Chief, IMF’s Asia and Pacific Department, and Krishna Srinivasan, Director of Asia and Pacific Department (APD) The region is likely...
News
Investment Thesis Barclays PLC (NYSE:BCS) share prices appear to have plateaued recently. In my view, this could be due to the reorganization that is...
News
By Seema Shah, Chief Global Strategist The September Consumer Price Index (CPI) showed that inflation continues to edge towards the Federal Reserve’s (Fed’s) 2%...
News
By Craig Bewick At a glance Treasury options traders began pricing the 2-year yield risk to the downside and 10 and 30-year to the...
News
The WisdomTree U.S. Efficient Core Fund (NYSEARCA:NTSX) is an interest asset allocation fund that effectively provides 1.5x leveraged returns to the traditional 60/40 portfolio....
News
Investment thesis Our current investment thesis is: CBIZ currently has a strong foundation from which to achieve MSD/HSD growth into the end of the...
News
Intro Relmada Therapeutics (NASDAQ:RLMD) is advancing its NMDA antagonist, REL-1017 (esmethadone), as a novel antidepressant for the treatment of major depressive disorder (MDD). After...
